ClinicalTrials.gg
CompletedNCT03083041Updated Mar 3, 2026Results posted

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

A Phase 2 interventional study of SHR-1210 and Apatinib in Carcinoma, Non-Small-Cell Lung, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 27
210 · median 58
Started
2017
with 2 others
Phase 2
17 of 27
4 open now
Registered
1st of 27
by date
Lead sponsor
7 of 27
Jiangsu HengRui Medicine Co., Ltd.

Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 17 in phase 2, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg, q2w in combination with Apatinib at two dose levels in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The study is composed of two parts. Part 1 of the study will determine the safety, tolerability and pharmacokinetics of SHR-1210 in combination with Apatinib.

Part 2 includes a randomized comparison of Apatinib 250mg/d or 500mg/d plus SHR-1210.

Subject's tumors will be screened at baseline for EGFR mutations, EML4-ALK translocation, and PD-L1 expression.But positive tumor PD-L1 expression will not be required for enrollment.

Read the detailed description

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). A disease-control rate of 61.1% and a mPFS of 4.7 months were showed in Apatinib phase II study in patients with NSCLC.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung

Keywords

  • SHR-1210
  • Apatinib
  • NSCLC
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects >/= 18 years and \</=70 years of age at the time of .
  2. Advanced predominantly NSCLC with at least one according to 1.1.
  3. Failure of of chemotherapy(Part 1); Failure of First line of chemotherapy(Part 2)
  4. (ECOG) performance status 0-1.
  5. Patients must have recovered from any AEs of prior treatments before randomization.
  6. Adequate bone marrow,liver and renal function as assessed by the following laboratory tests conducted within 1 week before randomization. HB ≥ 90g/L; ≥1.5×10E+9/L; ≥100×10E+9/L; and AST \< 1.5×; ≤1×ULN; Cr ≤1.5×ULN or CL≥60 ml/min.
  7. of at least three months.
  8. Male or female participants of must be willing to use an adequate method of starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug.
  9. Written informed consent and the willingness and ability to comply with all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including male ≥ 450 ms, female≥ 470 ms).
  2. Severe or uncontrolled systemic disease such as hypertension (systolic pressure >/= 140 mm Hg and/or diastolic pressure >/= 90 mm Hg), and Grade III-IV cardiac insufficiency, according to criteria or echocardiography check: \<50%.
  3. Factors to affect oral administration (inability to swallow tablets,GI tract resection, chronic bacillary diarrhea and intestinal obstruction).
  4. Coagulation disfunction,hemorrhagic tendency or receiving anticoagulant therapy
  5. >/= 2 pneumorrhagia or >/= CTCAE 3 hemorrhage in other organs within 4 weeks.
  6. Bone fracture or wounds that was not cured.
  7. Arterial thrombus or phlebothrombosis within 6 months and taking anticoagulant agents.
  8. Mental diseases and psychotropic substances abuse.
  9. Previous treatment with an trial agent within 4 weeks
  10. Proteinuria ≥ (++) or 24 hours total urine protein > 1.0 g.
  11. Other coexisting malignant disease (except basal-cell carcinoma and carcinoma in situ of uterine cervix).
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    SHR-1210,200mg,q2w plus apatinib 250mg/d

    SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD

    Biological: SHR-1210 · Drug: Apatinib

  • Experimental
    SHR-1210,200mg,q2w plus apatinib 500mg/d

    SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD

    Biological: SHR-1210 · Drug: Apatinib

  • Experimental
    SHR-1210,200mg,q2w plus apatinib 375mg/d

    SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD

    Biological: SHR-1210 · Drug: Apatinib

Interventions

  • BiologicalSHR-1210

    SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg

  • Apatinib tablet will be administered orally,once daily until progression

    Also known as: Apatinib Mesylate

06

What researchers measure

Primary outcomes

  1. Incidence and Grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of participants with Adverse Events and Serious Adverse Events

    Time frame: from signing the informed consent form to safety follow-up, 61 months

  2. Objective Response Rate (ORR):

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: from first administration to progressive disease or initiation of new anti-cancer therapy, 61 months

07

Results

Posted Mar 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneDriver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg Group
Started130432512
Treated130432512
Completed7525131
Not completed55181211

Outcome measures

PrimaryIncidence and Grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)

Number of participants with Adverse Events and Serious Adverse Events

Time frame:
from signing the informed consent form to safety follow-up, 61 months
Reported as:
Number · participants
Incidence and Grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsDriver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg Group
Number of Subjects with AEs130432512
Number of Subjects with SAEs822197
PrimaryObjective Response Rate (ORR):

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
from first administration to progressive disease or initiation of new anti-cancer therapy, 61 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR):
Percentage of participantsDriver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg Group
Objective Response Rate (ORR):28.5 (20.9 to 37.0)18.6 (8.4 to 33.4)40.0 (21.1 to 61.3)16.7 (2.1 to 48.4)

Adverse events

Collected over from signing the informed consent form to safety follow-up, 61 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apatinib 250 mg Group48/198 (24.2%)112/198 (56.6%)197/198 (99.5%)
Apatinib 375 mg Group3/12 (25%)7/12 (58.3%)12/12 (100%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventApatinib 250 mg GroupApatinib 375 mg Group
Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)19/1982/12
Immune-mediated hepatitisHepatobiliary disorders2/1982/12
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders8/1981/12
PneumothoraxRespiratory, thoracic and mediastinal disorders2/1981/12
Gastrointestinal haemorrhageGastrointestinal disorders0/1981/12
Venous thrombosis limbVascular disorders0/1981/12
Hepatic function abnormalHepatobiliary disorders11/1980/12
DeathGeneral disorders10/1980/12
PneumoniaInfections and infestations8/1980/12
PneumonitisRespiratory, thoracic and mediastinal disorders5/1980/12
Most frequent other events
Showing 10 of 105
Most frequent other events
EventApatinib 250 mg GroupApatinib 375 mg Group
RashSkin and subcutaneous tissue disorders66/19811/12
HypertensionVascular disorders126/19810/12
Decreased appetiteMetabolism and nutrition disorders66/1989/12
ProteinuriaRenal and urinary disorders125/1989/12
Aspartate aminotransferase increasedInvestigations106/1988/12
AstheniaGeneral disorders70/1987/12
Alanine aminotransferase increasedInvestigations89/1987/12
PyrexiaGeneral disorders56/1986/12
Weight decreasedInvestigations41/1986/12
CoughRespiratory, thoracic and mediastinal disorders63/1986/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Driver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg GroupTotal
Median59.0 (35 to 70)55.0 (33 to 69)61.0 (47 to 69)55.5 (43 to 68)59 (33 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Driver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg GroupTotal
Female28186254
Male102251910156
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Driver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg GroupTotal
American Indian or Alaska Native00000
Asian130432512210
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Driver Gene Negative PopulationDriver Gene Positive PopulationCohort 4Apatinib 375 mg GroupTotal
China130432512210
08

Study locations

1 site
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
09

References and documents

Publications

  • Gao G, Ni J, Wang Y, Ren S, Liu Z, Chen G, Gu K, Zang A, Zhao J, Guo R, He J, Lin X, Pan Y, Ma Z, Wang Z, Fan M, Liu Y, Cang S, Yang X, Li W, Wang Q, Zhou C. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration. Transl Lung Cancer Res. 2022 Jun;11(6):964-974. doi: 10.21037/tlcr-22-22. PubMed 35832447 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2022, 61 months.

Results were first posted in Mar 2026, 3 years 10 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 61 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2017
First posted
Mar 17, 2017
StartActual
Mar 13, 2017
Primary completionActual
Apr 22, 2022
CompletionActual
Apr 22, 2022
Results first posted
Mar 3, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03083041
Responsible party
Sponsor
First posted
Mar 17, 2017
Start date
Mar 13, 2017
Primary completion
Apr 22, 2022
Completion
Apr 22, 2022
Results posted
Mar 3, 2026
Last update
Mar 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion